The UMass Metabolic Disease Research Center (MDRC) provides industry-standard preclinical drug trial studies combined with metabolic, physiologic, functional, analytical, and molecular tests for in vivo validation of drug candidates for academic and industry researchers. The services include standardized drug efficacy tests, toxicity tests, and acute/chronic drug delivery modalities using intravenous (IV), intraperitoneal (IP), and subcutaneous (SC) injections, oral gavage (PO), and implantation of osmotic pumps (OP). These services address a rising need to conduct high-quality drug trial tests with rigor and reproducibility, identifying the next generation of drugs to treat type 2 diabetes and metabolic liver disease (NAFLD and NASH).